Original article by Jessica Sier
The Australian Financial Review – Page: 18 : 8-Jan-16
Australia’s benchmark S&P/ASX 200 Index shed 2.7 per cent during 2015. However, an index of 40 biotechnology companies which was compiled by "Biotech Daily" gained 22 per cent. ImpediMed, Opthea, Nanosonics, Starpharma and Mesoblast are among the biotechnology stocks that could potentially perform well in 2016.
STANDARD AND POOR’S ASX 200 INDEX, BIOTECH DAILY, IMPEDIMED LIMITED – ASX IPD, OPTHEA LIMITED – ASX OPT, NANOSONICS LIMITED – ASX NAN, STARPHARMA HOLDINGS LIMITED – ASX SPL, MESOBLAST LIMITED – ASX MSB, HATCHTECH PTY LTD, SPINIFEX PHARMACEUTICALS PTY LTD, FIBROTECH THERAPEUTICS PTY LTD, QRXPHARMA LIMITED – ASX QRX, OSPREY MEDICAL INCORPORATED – ASX OSP, GI DYNAMICS INCORPORATED – ASX GID, CANACCORD GENUITY (AUSTRALIA) LIMITED, COCHLEAR LIMITED – ASX COH, CSL LIMITED – ASX CSL, RESMED INCORPORATED – ASX RMD